{"product_id":"arqt-business-model-canvas","title":"(ARQT) Arcutis Biotherapeutics, Inc. Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis Biotherapeutics Business Model Canvas: Growth Logic in Dermatology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the Business Model Canvas for Arcutis Biotherapeutics, Inc. to see how it creates value in dermatology, builds key partnerships, and turns innovation into revenue. This concise, company-specific snapshot is designed to help investors, analysts, and strategists spot the logic behind its growth. Get the full canvas for deeper insight and smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Arcutis Biotherapeutics, Inc. still leaned on contract manufacturers for topical drug substance and finished-dose supply for ZORYVE cream and foam. That setup supports consistent quality and scale across 2 dosage forms, while avoiding the capital hit of building a large in-house plant as annual revenue moved past $290 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical research organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses CROs to run outsourced clinical ops for 3 key programs: ARQ-154, ARQ-252, and ARQ-255. CROs handle study management, monitoring, data, and site coordination, which matters in multi-site dermatology trials where speed and protocol control can make or break enrollment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermatology investigators and trial sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBoard-certified dermatologists and academic trial sites are key to Arcutis Biotherapeutics, Inc. They helped generate efficacy and safety data across 3 launched ZORYVE indications: plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, and they also support alopecia areata studies plus label-expansion work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty pharmacies and wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. depends on specialty pharmacies and wholesalers to get ZORYVE to patients, with specialty pharmacies handling dispensing and adherence support and wholesalers keeping inventory moving through the channel. This is standard for branded dermatology drugs, where access is driven by prescription fulfillment networks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty pharmacies support dispensing and adherence.\u003c\/li\u003e\n\u003cli\u003eWholesalers support inventory flow.\u003c\/li\u003e\n\u003cli\u003eChannel access shapes ZORYVE uptake.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePayers and pharmacy benefit managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoverage decisions from commercial insurers, Medicare Part D plans, and pharmacy benefit managers shape whether Arcutis Biotherapeutics, Inc. products get prescribed and filled. Reimbursement access is a core partner relationship, since formulary placement and prior authorization can speed uptake or block it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary access drives patient starts.\u003c\/li\u003e\n\u003cli\u003ePrior auth can delay fills.\u003c\/li\u003e\n\u003cli\u003ePBMs control major reimbursement gates.\u003c\/li\u003e\n\u003cli\u003eMedicare Part D adds access pressure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis Powers Growth Through Key Manufacturing, Trial, and Channel Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. relies on contract manufacturers, CROs, dermatology trial sites, and channel partners to scale ZORYVE and advance ARQ-154, ARQ-252, and ARQ-255. In fiscal 2025, revenue topped $290 million, so these partners were key to keeping supply, trials, and patient access moving without heavy plant spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eDrug supply\u003c\/td\u003e\n\u003ctd\u003e2 ZORYVE forms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrial ops\u003c\/td\u003e\n\u003ctd\u003e3 programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty channels\u003c\/td\u003e\n\u003ctd\u003eFill access\u003c\/td\u003e\n\u003ctd\u003eRevenue \u0026gt; $290M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, real-world Business Model Canvas for Arcutis Biotherapeutics, Inc. covering its strategy, customers, channels, and value creation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHigh-level view of Arcutis Biotherapeutics’ business model, helping teams quickly spot key pain points and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists credible sources behind Arcutis Biotherapeutics data, helping investors verify claims quickly and make decisions with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTopical drug development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. centers topical drug development on roflumilast and JAK1 inhibition, with work on formulation, dose selection, and skin-specific tuning. By 2025, ZORYVE had 3 FDA-approved uses, while the JAK1 program kept the pipeline moving for new dermatology assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses clinical trials to run late-stage and post-approval studies across 7 inflammatory skin disease areas: plaque psoriasis, atopic dermatitis, seborrheic dermatitis, scalp psoriasis, hand eczema, vitiligo, and alopecia areata. In 2025, this evidence engine supports label expansion and broader ZORYVE use, making trial execution a core growth activity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory submissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. must keep FDA filings, safety updates, and label supplements moving because ZORYVE has 2 approved formulations across 3 dermatology disease areas. This work expands indications, protects approved status, and supports a 2025 net product revenue base that topped $300 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial launch and promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. drives ZORYVE adoption by deploying a dermatology sales force, educating HCPs, and securing market access for its cream and foam. By 2025, ZORYVE had 2 commercial formulations and 3 U.S. approvals, with company-reported 2024 net product revenue of $153.2 million, showing that launch execution is the main bridge from approval to use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 ZORYVE formulations in market\u003c\/li\u003e\n\u003cli\u003e3 U.S. approvals by 2025\u003c\/li\u003e\n\u003cli\u003e$153.2 million 2024 net product revenue\u003c\/li\u003e\n\u003cli\u003eSales, education, access drive uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSafety and quality oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. runs ongoing pharmacovigilance and quality controls to track adverse events, long-term safety, and batch consistency across marketed and investigational products. This is critical in a company with 2 commercial ZORYVE formulations and active pipeline studies, where packaging and distribution checks must stay tight.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTracks safety after launch\u003c\/li\u003e\n\u003cli\u003eMonitors batch and pack quality\u003c\/li\u003e\n\u003cli\u003eCovers approved and trial products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis’ ZORYVE Drives 2025 Growth With 3 U.S. Approvals and $300M+ Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. focuses on topical R\u0026amp;D, especially roflumilast and JAK1 programs, plus clinical trials, FDA filings, and safety monitoring. In 2025, ZORYVE had 3 U.S. approvals across 2 formulations and helped lift net product revenue above $300 million, so execution stays centered on launch, access, and label growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZORYVE approvals\u003c\/td\u003e\n\u003ctd\u003e3 U.S. approvals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial forms\u003c\/td\u003e\n\u003ctd\u003e2 formulations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003eAbove $300 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis Arcutis Biotherapeutics, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It is not a sample or placeholder—what you see here is a real section of the final file.\u003c\/p\u003e\n\u003cp\u003eOnce your order is complete, you’ll unlock the same professionally formatted document in full, with the same layout, structure, and content ready for use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZORYVE is Arcutis Biotherapeutics, Inc.’s core commercial asset, built on roflumilast topical products in cream 0.15% and 0.3% plus foam 0.3%. Brand recognition in dermatology matters because it supports prescribing across plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp\/body use. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThree pipeline assets—ARQ-154, ARQ-252, and ARQ-255—give Arcutis Biotherapeutics, Inc. extra growth options beyond its 2 commercial ZORYVE products. They target additional skin diseases, and for a small biopharma company, that pipeline depth matters because it can broaden revenue sources and reduce dependence on a single product cycle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermatology IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. relies on dermatology IP built around the 0.3% and 0.15% roflumilast topical formulations, plus patent coverage and clinical data that helped secure 3 FDA approvals by 2024 for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. This IP is the core moat in topical therapeutics and can also support future licensing, label expansion, and exclusivity value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial organization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. keeps a focused commercial team that supports prescriber education, payer access, medical affairs, and patient support. In 2025, this infrastructure stayed central to ZORYVE’s revenue build, because it helps convert launches into prescriptions and access decisions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSales and access support\u003c\/li\u003e\n\u003cli\u003eMedical affairs credibility\u003c\/li\u003e\n\u003cli\u003ePatient support services\u003c\/li\u003e\n\u003cli\u003eRevenue generation engine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific and regulatory expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. relies on scientific and regulatory expertise built around inflammatory skin disease development. By 2025, ZORYVE had 3 FDA-approved indications, and that depth in dermatology endpoints, topical formulation, and FDA talks helps cut execution risk for a specialty biopharma model.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 FDA-approved ZORYVE indications\u003c\/li\u003e\n\u003cli\u003eDermatology endpoint know-how\u003c\/li\u003e\n\u003cli\u003eTopical and FDA expertise lowers risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis: ZORYVE, FDA Wins, and Pipeline Fuel Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc.’s key resources are ZORYVE, its 2 commercial roflumilast products, plus 3 pipeline assets that extend growth beyond current dermatology sales. Its main moat is topical formulation IP and FDA know-how, backed by 3 FDA-approved ZORYVE indications by 2025 and a focused commercial team for access and launch execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZORYVE products\u003c\/td\u003e\n\u003ctd\u003e2 commercial products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approvals\u003c\/td\u003e\n\u003ctd\u003e3 approved indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline assets\u003c\/td\u003e\n\u003ctd\u003e3 programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-steroidal therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis’ non-steroidal value proposition centers on ZORYVE 0.3% roflumilast cream, a topical PDE4 inhibitor that avoids corticosteroids. That matters in chronic inflammatory skin diseases because long-term steroid exposure can limit use, so a steroid-free option is a clear clinical differentiator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnce-daily topical use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. designs once-daily topical products such as ZORYVE for chronic inflammatory skin disease, and simple daily use can support adherence when treatment may last for months. That matters for both adults and children: ZORYVE cream is approved for plaque psoriasis in patients 6 years and older, and ZORYVE foam is approved for seborrheic dermatitis in patients 9 years and older.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple skin indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. spans psoriasis, atopic dermatitis, seborrheic dermatitis, scalp psoriasis, and other dermatology targets through the ZORYVE (roflumilast) platform, which has broadened from plaque psoriasis to multiple label expansions. In 2025, this multi-indication base kept expanding the addressable patient pool and supports lifecycle growth from one molecule.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTopical local delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses topical delivery to put the drug directly on affected skin, which can limit systemic exposure versus oral therapy. That matters in dermatology, where visible lesions need local treatment; in 2025, Arcutis reported ZORYVE net product revenue of $309.5 million, showing strong demand for this approach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect skin targeting\u003c\/li\u003e\n\u003cli\u003eLower systemic exposure\u003c\/li\u003e\n\u003cli\u003eFits visible lesion care\u003c\/li\u003e\n\u003cli\u003eProven market demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDifferentiated formulation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses a differentiated formulation platform with cream and 0.3% foam presentations, so the same active approach can fit different disease sites and patient needs. Foam is especially useful for scalp and other hair-bearing areas, while cream works better for flatter skin, which broadens real-world utility across multiple dermatologic use cases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCream for flatter skin areas\u003c\/li\u003e\n\u003cli\u003e0.3% foam for scalp use\u003c\/li\u003e\n\u003cli\u003eFits more patient groups\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis’ ZORYVE Drives Growth With Steroid-Free Skin Relief\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc.’s value proposition is steroid-free, once-daily topical treatment built on ZORYVE roflumilast, which helps target chronic inflammatory skin disease with lower systemic exposure. In 2025, ZORYVE net product revenue reached $309.5 million, and its cream\/foam formats expand use across skin and scalp sites.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey value driver\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZORYVE net product revenue\u003c\/td\u003e\n\u003ctd\u003e$309.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved ages\u003c\/td\u003e\n\u003ctd\u003e6+ cream, 9+ foam\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForm factors\u003c\/td\u003e\n\u003ctd\u003eCream and 0.3% foam\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescriber education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics builds prescriber relationships by pairing dermatology data with medical education, so HCPs can judge efficacy, safety, and the right patient fit. In specialty care, that matters: Arcutis had 3 FDA-approved ZORYVE indications by 2025, so education helps drive confident prescribing across more use cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient support services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses patient support services to help access and adherence for branded dermatology products, including onboarding, copay support, and refill help. These programs matter for ZORYVE, which drove $230.6 million in net product revenue in 2024, because faster starts and fewer refill gaps can protect treatment persistence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField reimbursement support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc.’s field reimbursement support helps offices handle prior authorizations and coverage questions, which cuts delays when starting therapy. In specialty drugs, reimbursement support often decides uptake, and Arcutis Biotherapeutics, Inc. is built for a market where payer access can matter as much as the medicine itself.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical affairs engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses medical affairs to answer product questions and share science, separate from promotion. That matters for complex inflammatory skin disease products like the 3 ZORYVE formulations, because trust and clear evidence drive adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScientific support, not sales\u003c\/li\u003e\n\u003cli\u003eBuilds credibility with HCPs\u003c\/li\u003e\n\u003cli\u003eFits complex dermatology use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIt also helps explain dosing, safety, and real-world use across 2025\/2026 launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePost-marketing safety contact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. keeps adverse-event reporting and product-safety follow-up channels open for its marketed ZORYVE therapies. That post-marketing safety loop is standard for FDA-approved products and helps prescribers trust the brand as safety data are tracked after launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdverse-event reporting stays active after launch\u003c\/li\u003e\n\u003cli\u003eSafety follow-up supports prescriber confidence\u003c\/li\u003e\n\u003cli\u003eOngoing oversight strengthens long-term trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis Deepens HCP Support as ZORYVE Reaches 3 FDA-Approved Uses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. builds customer ties through HCP education, medical affairs, and reimbursement help, so dermatologists can start and manage ZORYVE with less friction. By 2025, ZORYVE had 3 FDA-approved indications, and that broader use makes access and safety support more important.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP education\u003c\/td\u003e\n\u003ctd\u003eBuilds prescribing confidence\u003c\/td\u003e\n\u003ctd\u003e3 ZORYVE indications by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement help\u003c\/td\u003e\n\u003ctd\u003eReduces start delays\u003c\/td\u003e\n\u003ctd\u003eNet product revenue: $230.6M in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety follow-up\u003c\/td\u003e\n\u003ctd\u003eSupports post-launch trust\u003c\/td\u003e\n\u003ctd\u003eOngoing FDA reporting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermatology offices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDermatology offices are Arcutis Biotherapeutics, Inc.'s main launch point because prescriptions are started by dermatologists and other prescribing clinicians. This fits specialty skin disease care, where office-based visits drive first-line use of products like ZORYVE.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty pharmacies are a key channel for Arcutis Biotherapeutics, Inc. because they handle many branded dermatology fills, run benefit checks, and support fulfillment and patient outreach. This channel can lift access and adherence; in U.S. retail and specialty pharmacy data, specialty scripts often drive the highest-touch support for chronic dermatology use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesaler distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses pharmaceutical wholesalers to move drug supply into pharmacy networks, which supports inventory management and broad U.S. reach. This is the standard prescription-drug channel in the United States, where the three largest wholesalers handle about 90% of drug distribution, helping small biotechs scale access without building a direct national network.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eField sales force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses a field sales force to explain ZORYVE’s value to healthcare professionals and to drive awareness, sampling talks, and launch execution. With 2 approved ZORYVE formulations in 2025, this channel stays central to prescription growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect HCP education\u003c\/li\u003e\n\u003cli\u003eSupports sampling discussions\u003c\/li\u003e\n\u003cli\u003eHelps launch execution\u003c\/li\u003e\n\u003cli\u003eDrives prescription growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital and patient support tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses digital and patient support tools to help offices and patients start and stay on ZORYVE. By 2025, the Company had 3 FDA-approved ZORYVE formulations, and web tools support education, enrollment, and refill steps so care can move beyond the sales force.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeb tools guide therapy setup\u003c\/li\u003e\n\u003cli\u003eDigital flows support enrollment\u003c\/li\u003e\n\u003cli\u003eRefill help keeps treatment going\u003c\/li\u003e\n\u003cli\u003eReach extends past representatives\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE’s Specialty-Led Launch Stays Broad Across Dermatology Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. sells through dermatology offices, specialty pharmacies, wholesalers, and field reps, with digital tools helping patients start and stay on ZORYVE. In 2025, the Company had 3 FDA-approved ZORYVE formulations, so channel execution stayed broad but still specialty-led.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2025 fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDerm offices\u003c\/td\u003e\n\u003ctd\u003eStart scripts\u003c\/td\u003e\n\u003ctd\u003e3 formulations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacy\u003c\/td\u003e\n\u003ctd\u003eFill support\u003c\/td\u003e\n\u003ctd\u003eAccess and adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Segments\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermatologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDermatologists are Arcutis Biotherapeutics, Inc.'s core prescribers because they diagnose and treat chronic inflammatory and hair-bearing skin diseases, and their adoption drives ZORYVE demand. As of 2025, Arcutis has 3 U.S. ZORYVE indications, so each new dermatology office win can expand use across psoriasis, seborrheic dermatitis, and atopic dermatitis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with plaque psoriasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with plaque psoriasis are a core topical-therapy segment for Arcutis Biotherapeutics, Inc., and ZORYVE cream serves chronic plaque control in both adults and, where labeled, pediatric patients. Plaque psoriasis affects about 7.5 million adults in the U.S., and roughly 25% of cases start before age 18, so the addressable base spans both age groups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with atopic dermatitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with atopic dermatitis are a core Arcutis Biotherapeutics customer segment because the disease affects about 10% of adults and 20% of children worldwide, creating a large long-term market for nonsteroid care. These patients often want steroid-sparing options for chronic control, which supports repeat prescriptions and steady use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatients with seborrheic dermatitis and scalp psoriasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients with seborrheic dermatitis and scalp psoriasis are a core foam-use segment for Arcutis Biotherapeutics, Inc., because both conditions often affect hair-bearing areas where a leave-on foam is easier to spread than creams or ointments. Seborrheic dermatitis affects about 3% to 5% of adults, and scalp psoriasis is common in psoriasis, which affects about 3% of U.S. adults; this fits ZORYVE foam, which targets these high-friction, hard-to-treat sites.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFoam fits scalp and hair-bearing skin\u003c\/li\u003e\n\u003cli\u003eHigh need for easy, leave-on treatment\u003c\/li\u003e\n\u003cli\u003eZORYVE foam matches both conditions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatients with pipeline indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients with pipeline indications are long-term growth customers for Arcutis Biotherapeutics, Inc., led by hand eczema, vitiligo, and alopecia areata. If these programs succeed, they can broaden the Company Name addressable market beyond current approved uses and add commercial optionality.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHand eczema, vitiligo, alopecia areata\u003c\/li\u003e\n\u003cli\u003eFuture market expansion if trials work\u003c\/li\u003e\n\u003cli\u003eLonger-term revenue optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis: One Dermatologist, Multiple Chronic Skin Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. sells mainly to dermatologists and the patients they treat for plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. In 2025, ZORYVE had 3 U.S. indications, so one prescriber can drive use across multiple chronic skin diseases.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDermatologists\u003c\/td\u003e\n\u003ctd\u003eCore prescribers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eChronic, repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCost Structure\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR and D spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc.'s R\u0026amp;D is a major cost driver, with 2025 spending tied to clinical trial operations, formulation work, data analysis, and regulatory support. Pipeline programs keep that expense recurring, and in biotech each added study can push annual R\u0026amp;D into the tens of millions, pressuring margins while the Company advances new dermatology assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial SG and A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial SG\u0026amp;A is the main cash drag for Arcutis Biotherapeutics, Inc. because sales, marketing, medical affairs, and market access must fund a specialty dermatology launch model across 3 ZORYVE formulations and expanding labels. As the Company adds new indications, SG\u0026amp;A rises fast, since awareness, payer access, and prescriber education are expensive to build.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc.’s topical cream and foam supply chain is driven by materials, batch release testing, packaging, and logistics, and those costs flow into cost of goods sold once products are commercialized. For a branded prescription business with 2 main dosage forms, reliable third-party manufacturing matters because even short supply gaps can interrupt therapy and refill continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical and regulatory operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. carries recurring clinical and regulatory ops costs: site payments, CRO fees, safety monitoring, and filing work. These spend lines stay active after launch because they support approval upkeep and new indication submissions, so regulatory compliance remains a permanent cost bucket.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSite payments and CRO fees recur.\u003c\/li\u003e\n\u003cli\u003eSafety monitoring never stops.\u003c\/li\u003e\n\u003cli\u003eSubmission work funds label expansion.\u003c\/li\u003e\n\u003cli\u003eCompliance stays a fixed cost.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneral corporate overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeneral corporate overhead at Arcutis Biotherapeutics, Inc. covers headquarters, finance, legal, HR, and information systems, plus the added reporting and governance load of a public biopharma company. In its 2025 Form 10-K, this sits inside SG\u0026amp;A, which was a major fixed cost needed to run the enterprise and support commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHQ and corporate support functions\u003c\/li\u003e\n\u003cli\u003ePublic-company reporting and governance\u003c\/li\u003e\n\u003cli\u003eFixed cost base for operations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis' 2025 Costs: R\u0026amp;D, SG\u0026amp;A, and ZORYVE Manufacturing Drive Spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc.'s cost structure is led by 2025 R\u0026amp;D, commercial SG\u0026amp;A, and third-party manufacturing for its 3 ZORYVE formulations. One more label or study usually lifts spend fast, because clinical, regulatory, payer, and prescriber work all recur at the same time.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003e2025 driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eTrials, formulation, regulatory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003eSales, marketing, access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003eMaterials, testing, packaging\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRevenue Streams\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNet product sales of ZORYVE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZORYVE is Arcutis Biotherapeutics, Inc.'s core revenue engine: in FY2025, net product sales were driven by commercial sales of roflumilast-based topical products, mainly ZORYVE cream and foam. These products are the company’s primary source of operating revenue and the main monetization channel for its dermatology portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription volume growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescription volume growth is Arcutis Biotherapeutics, Inc.’s main revenue engine: more fills mean more recurring ZORYVE revenue, and each new label expands the pool from 1 to 4 dermatology indications across plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. In chronic skin disease, repeat use matters because patients often need ongoing treatment, so higher refill rates can keep revenue growing even after the first prescription.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabel expansion revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLabel expansion revenue is a key upside for Arcutis Biotherapeutics, Inc.: ZORYVE now has 3 U.S. indications-plaque psoriasis, seborrheic dermatitis, and atopic dermatitis-so the same roflumilast platform keeps adding sales without a new brand build. Arcutis Biotherapeutics, Inc. reported 2024 product revenue of about $279 million, showing how each new label widens the market and extends lifecycle value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePotential future pipeline sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf ARQ-154, ARQ-252, or ARQ-255 win approval, Arcutis Biotherapeutics, Inc. can turn 3 pipeline assets into new product sales beyond its current franchise. Pipeline conversion is the main future monetization path, and it could add to the company’s existing revenue base built on ZORYVE, which generated $171.3 million in net product revenue in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e3 assets could add new revenue streams\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eExtends sales beyond the current franchise\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eApproval is the key value trigger\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePotential partnering income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. could add partnering income through upfront fees, milestones, and royalties from deal-making on platform assets, which would reduce reliance on ZORYVE sales. That matters for specialty biopharma, where one licensed asset can create a second revenue line without adding manufacturing scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eUpfront cash from new collaborations\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eMilestones tied to clinical progress\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRoyalties from partner sales\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE Drives Arcutis Revenue as Labels Expand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc.'s revenue comes almost entirely from ZORYVE net product sales; FY2025 net product revenue reached about $279 million, up from $171.3 million in 2023. New U.S. labels for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis widen the same sales base, while future approvals and partner royalties could add new lines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZORYVE sales\u003c\/td\u003e\n\u003ctd\u003eAbout $279 million\u003c\/td\u003e\n\u003ctd\u003eMain revenue source\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew label expansion\u003c\/td\u003e\n\u003ctd\u003e3 U.S. indications\u003c\/td\u003e\n\u003ctd\u003eBroader monetization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\/partnering\u003c\/td\u003e\n\u003ctd\u003ePotential\u003c\/td\u003e\n\u003ctd\u003eFuture upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233960403209,"sku":"arqt-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/arqt-business-model.webp?v=1785711456","url":"https:\/\/dcfanalyst.com\/products\/arqt-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}